4 Payout Plays To Plough Your Cash Into: BT Group plc, GlaxoSmithKline plc, Carillion plc And Barratt Developments PLC

Royston Wild explains why dividend hunters should check out BT Group plc (LON: BT.A), GlaxoSmithKline plc (LON: GSK), Carillion plc (LON: CLLN) and Barratt Developments PLC (LON: BDEV).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at four payout powerhouses that would supercharge any stocks portfolio.

BT Group

On first look BT (LSE: BT-A) may not be the most appetising payout pick out there, the firm having lagged the average market yield for some time now. And this trend is expected to continue for the medium term at least — the City expects the London company to shell out a reward of 14.4p per share for the 12 months ending March 2016, yielding just 3.2% versus 3.4% for the wider FTSE 100.

Still, I believe that BT’s terrific long-term earnings prospects should keep the firm’s ultra-progressive dividend policy in business. Indeed, the firm has lifted the total payment at a blistering compound annual growth rate of 13.8% during the past five years as profits have rocketed higher. BT is anticipated to raise the payout to 15.7p in 2017, yielding 3.5%, and with a rising subscriber base driving the bottom line higher and cash flows also on the rise, I expect dividends to continue blasting skywards.

GlaxoSmithKline

The capital-intensive nature of GlaxoSmithKline’s (LSE: GSK) operations have cast some doubts over the scale of shareholder rewards in future years. To try and assuage these fears the pharma play has vowed to shell out a dividend of 80p per share right through to the close of 2017, a figure that creates an almost-unrivalled yield of 5.8%.

Of course there is no guarantee that GlaxoSmithKline will be able to make good on these promises, particularly as vast sums are required for the Brentford firm to develop new drugs and put to bed the enduring problem of patent losses. But I believe that GlaxoSmithKline’s pedigree in getting product from lab bench to market — its exciting mepolizumab anti-asthma drug received FDA approval for adults just last month — combined with further rounds of extensive cost-cutting should keep dividends trucking along at generous levels.

Carillion

I am convinced that construction giant Carillion’s (LSE: CLLN) ability to grind out contract win after contract win with major private- and public-sector customers should maintain steady dividend growth as the bottom line swells. Even though construction data remains patchy, on a longer-term time horizon I believe the fruits of an improving UK economy should continue sending business Carillion’s way.

Meanwhile, the building play’s ability to throw up massive amounts of cash should copper-bottom investor confidence in dividends looking ahead, in my opinion. This view is shared by the number crunchers, who expect the business to lift the dividend from 17.75p per share in 2015 to 18.2p in 2016, and again to 18.9p in the following year. Consequently Carillion carries vast yields of 5.2% and 5.4% for these periods.

Barratt Developments

Make no mistake: the colossal gap between housing supply and demand in Britain is not likely to be fixed anytime soon. Such a scenario is playing into the hands of homebuilders such as Barratt Developments (LSE: BDEV), and with interest rates set to remain low well into 2016 at the earliest; lending products becoming cheaper and cheaper for new buyers; and owners becoming increasingly reluctant to put their properties on the market, the imbalance is only likely to get worse.

With home prices likely to keep surging as a result, the earnings outlook at the likes of Barratt Developments is as strong as at any time in recent memory. Subsequently the company is predicted to transform last year’s 10.3p-per-share dividend to 22.9p in the year concluding June 2016, producing a chunky yield of 3.6%. And this readout leaps to 4.5% for 2017 amid expectations of a 28.6p payment.

Royston Wild owns shares of Barratt Developments. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK money in a Jar on a background
Investing Articles

A SIPP seems to offer investors free money – is there a catch?

This writer doesn't believe in magic money trees, but does see the offer of tax relief within a SIPP as…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Here’s what £10,000 invested in Greggs shares a year ago’s worth now

Given Greggs large shop network and simple business formula, could owning the shares help this writer build wealth? Maybe --…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

Recent BT share price performance is jaw-dropping but can it continue?

Harvey Jones is stunned by how well the BT share price has weathered recent stock market volatility. Can the FTSE…

Read more »

A senior man using hiking poles, on a hike on a coastal path along the coastline of Cornwall.
Investing Articles

Is the stock market correction a once-in-a-decade chance to target a million-pound SIPP?

After recent volatility Harvey Jones can see plenty of value FTSE 100 stocks to help investors build wealth in a…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

How to target a £10k annual income from just one year’s £20,000 Stocks and Shares ISA allowance

Today is the start of the new financial year giving us all a a fresh Stocks and Shares ISA allowance.…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Rolls-Royce shares have gone nowhere this year. Is that a warning sign?

Rolls-Royce shares stand within spitting distance of where they began the year. Has the company's long run of strong share…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

£5,000 invested in Tesla stock on Christmas Eve is now worth…

Tesla stock is stuck in reverse at the moment. This year, it has fallen by around 15%. Is there potential…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

2 UK dividend stocks to consider buying in April

High-quality established businesses with reliable cash flows often make for great dividend stocks. Here are two for investors to take…

Read more »